151 results about "Functional gastrointestinal disorder" patented technology

A method of treating chronic disorders associated with the presence of abnormal microflora or an abnormal distribution of microflora in the gastrointestinal tract involves removing the host's existing enteric microflora and substitution of feces from a disease screener donor or composition comprising microorganism selected from the group consisting of Bacteroides and E. coli.

The present invention relates to the use of a therapeutic or nutraceutical composition for the treatment of a gastrointestinal disorder, namely ulcerative colitis. In addition, the present invention provides methods of treating subjects suffering from gastrointestinal disorders such as ulcerative colitis.

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

Devices, systems and methods are disclosed for treating or preventing gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders. The methods comprise transmitting impulses of energy non-invasively to selected nerve fibers, particularly those in a vagus nerve. The methods provide damaged interstitial cells of Cajal (ICC) with trophic factors via vagal afferent nerve fibers, thereby reversing ICC damage, and as a consequence improving gastric motility. The methods also increase levels of inhibitory neurotransmitters in the brain so as to decrease neural activity within the area postrema, or they deactivate a resting state neural network containing parts of the anterior insula and anterior cingulate cortex, which will thereby reduce abnormal interoception and visceral hypersensitivity.

The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients, esophageal ulcers in immunocompromised patients, idiopathic gastric acid hypersecretion, gastroparesis, gastrointestinal motility disorders, Zollinger-Ellison syndrome, short bowel syndrome, emesis, regurgitation, early satiety, chronic sore throat, abdominal pain, abdominal bloating, nausea, sour stomach, diarrhea, constipation, bacterial infections, refractory ulcers, gastrointestinal disorders induced by NSAIDs, Barrett's esophagus, gastrointestinal disorders caused by steroids, gastrointestinal disorders induced by cholinergic compounds, and fungal or viral-induced ulcers in the gastrointestinal tract by administering a therapeutically effective amount of at least one proton pump to a patient in need thereof. The invention also provides on demand relief of symptoms associated with gastroesophageal reflux disease (GERD), and provides relief from symptoms caused by the consumption of excessive amounts of food and/or alcohol by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof. The invention also provides methods for treating parasitic infections, such as malaria, by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof.

The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments may be included. This method may be useful as a new and safer treatment for IBS and other functional gastrointestinal disorders. The action of the peppermint oil is effective as a modulator of gastrointestinal motility and sensation. Chlorophyll may improve bowel activity by stimulation of secretion and motility. This is the first description of this unique mixture of these natural products for the treatment of gastrointestinal conditions.

The invention relates to a TCM prescription capable of replenishing qi to invigorate the spleen, belonging to the TCM field. The technology scheme consists of the following materials in certain ratios: astragalus (30), campanumaea pilosula (12), dried ginger (10), atractylodes rhizome (15), poria (12), dried orangepeel, white cardamom seed (12) and liquorice (9). The medicine has the effect of replenishing spleen and releasing pain. Among the materials, the astragalus, campanumaea pilosula and atractylodes rhizome can replenish spleen and support the healthy energy; the dried ginger, white cardamom seed and dried orangepeel can warm the middle energizer to dispel cold and regulate circulation and release pain; the poria can invigorate spleen to remove dampness and the liquorice can replenish spleen and reconcile all drugs. The combined prescription has the ability of replenishing qi to invigorate the spleen, warming channels and releaving pain. The invention can mainly cure the spleen-yang deficiency patients suffering chronic gastritis, peptic ulcer, chronic enteritis, gastroptosia, malnutrition after gastrectomy, gastrointestinal dysfunction and malabsorption syndromes.

The invention provides a medicinal composition for treating digestive system dysfunction. The medicinal composition is characterized by comprising the following components in parts by weight: 10-25 parts of ginseng, 10-25 parts of bighead atractylodes rhizome, and 12-25 parts of poria. The medicinal composition is particularly suitable for treating gastrointestinal dysfunction after radiotherapy or chemotherapy, is good in curative effect, and does not have toxic or side effect; the patients have good tolerance and can easily accept the medicinal composition; the treatment cost is low. The medicinal composition can be used for treating gastrointestinal dysfunction after radiotherapy or chemotherapy independently, and also can be used for treating malignant tumor diseases by combining radiotherapy or chemotherapy.

The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum PS128 deposited under DSMZ Accession No. DSM 28632. The present invention further provides a composition that comprises Lactobacillus plantarum subsp, plantarum PS128 and a carrier. Moreover, the present invention provides a method for prophylaxis or treatment of a stress-induced disorder in a subject that comprises a step of administering an effective amount of Lactobacillus plantarum subsp. plantarum PS128 to the subject. The present invention also provides a method for prophylaxis or treatment of a functional gastrointestinal disorder in a subject that comprises a step of administering an effective amount of Lactobacillus plantarum subsp. plantarum PS128 to the subject.

The invention relates to a novel oral enteric preparation which is composed of 0.1-1000mg of Grel drugs, or medically acceptable salts, ester or derivatives, 37.5-325mg of aspirin and at least one medically acceptable load, wherein the Grel drugs, or medically acceptable salts, esters or derivatives are clopidogrel, prasugrel, brilinta, sarpogrelate, ozagrel, anagrelide, pamicogrel, or medically acceptable salts, ester or derivatives, preferably, clopidogrel sulfate. The oral enteric preparation is used for curing acute coronary syndrome (ACS), angor pectoris, stroke, myocardial infarction or cardia cerebrovascular diseases of patients. According to the oral enteric preparation, adverse reactions such as functional gastrointestinal disorders, nausea, vomit, gastritis, concealed hemorrhage, ulcer exacerbation and gastrointestinal bleeding caused by strong stimulus of aspirin to stomach can be avoided.

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I

The invention relates to enzyme dietary fiber and a preparation technology thereof. The enzyme dietary fiber comprises the following raw materials in parts by weight: 30-50 parts of enzyme powder, 1.5-3 parts of fructo-oligosaccharides, 10-15 parts of polydextrose, 15-25 parts of galacto-oligosaccharides, 5-8 parts of oat flour, and 6-10 parts of herba portulacae powder. The preparation technology of the enzyme dietary fiber comprises the following steps of: taking the raw materials and carrying out mixing, adding auxiliary materials, preparing the mixture into desired dosage forms, and carrying out sterilization so as to obtain the enzyme dietary fiber. Enzymes prepared by a special technology is adopted as the main raw material of the enzyme dietary fiber, other raw materials are matched, and related processes are combined so as to fundamentally solve constipation and gastrointestinal dysfunction; moreover, the enzyme dietary fiber is safe, free of any toxic and side effects, and free of drug dependence. Effective rate of the enzyme dietary fiber is up to 95% or higher.

The present invention relates to novel imidazole compounds having a positive allosteric GABA_B receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA_B agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

A weight-losing and lipid-lowering health care product relates to a health care product. The weight-losing and lipid-lowering health care product can solve the problems of gastrointestinal functional disorders, anemia, diabetes, renal dysfunction, weight rebound phenomenon and toxic and side effects of drugs when in administration of the existing weight-losing health care products or the lipid-lowering health care products by a person. The weight-losing and lipid-lowering health care product is composed of a tablet A and a table B; wherein, the tablet A is composed of chitosan, L-carnitine, chromium picolinate, calcium pyruvate and excipients; and the tablet B is composed of mixed vitamins, mixed minerals, linolenic acid and the excipients. The weight-losing and lipid-lowering drug of the invention can reduce the body weight for 3.17 plus or minus 1.56Kg after 45 days, lower the body fat for 2.83 plus or minus 1.19Kg and significantly reduce the subcutaneous fat of other parts; the average decrease rate of cholesterol is 10.48 plus or minus 5.11 percent, the average decrease rate of triglyceride is 19.57 plus or minus 8.12 percent, the total effective rate is 52.94 percent, the effects of weight-losing and lipid-lowering are significant, the weight-losing and lipid-lowering drug has no toxicity or side effects and no weight rebound.

The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating motor complex (MMC) is effective or malfunction of gastric motility or increased motilin secretion is observed, such as hypermotilinemia, imitable bowel syndrome, dyspepsia, including gallbladder dyspepsia, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, acute infectious diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, functional gastrointestinal disorders, chemotherapy-induced nausea and vomiting (emesis), post-operative nausea and vomiting, cyclic vomiting syndrome and functional vomiting. Accordingly, methods of treating such disorders with such macrocyclic compounds and pharmaceutical compositions thereof are also provided in addition to methods of modulating the migrating motor complex.

The present invention provides an agent and a food for the prophylaxis or improvement of a functional gastrointestinal disorder, which contains, as an active ingredient, at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof.

A health product with bee products as material comprises the following weight ratio materials: honey 15 to 20, bee pollen 40 to 50, honeycomb 20 to 30, beeswax 6 to 10, propolis 0.5 to 1.5; the beneficial effects is: the products of the present invention has health care beauty, can therapy gastrointestinal dysfunction, endocrine imbalance, adjust nerve balance, anti radiation, antimicrobial, anti-inflammatory and analgesic, antitoxin, stasis-resolving, support various nutrition, has hematopoietic function, improve cell regeneration, promote immunity function of human body obviously, soften blood vessel, brain-health and refresh, promote brain cell growth etc.

The invention discloses a Chinese herb extract composition for treating functional gastrointestinal disorder or irritable bowel syndrome, a preparation method and application of the composition to preparation of a medicine. The Chinese herb extract composition comprises the following Chinese medicinal herb extracts in parts by weight: 13-29 parts of langehead atractylodes rhizome extract I, 18-57 parts of langehead atractylodes rhizome extract II, 13-53 parts of radix paeoniae alba extract, 6-32 parts of pericarpium citri reticulatae extract and 2-27 parts of divaricate saposhnikovia root extract, wherein the langehead atractylodes rhizome extract I is an extract of a distillation method or supercritical extraction method; the langehead atractylodes rhizome extract II is a water extract; the radix paeoniae alba extract is an alcohol extract; the pericarpium citri reticulatae extract is an alcohol extract; the divaricate saposhnikovia root extract is an aqueous extract or supercritical extract. According to the Chinese herb extract composition, the conventional view that co-decocting or total extracting of a Chinese herbal compound is superior to respective extracting of each Chinese medicinal herb is overcome, the pharmacological effect is remarkably improved through optimized combined treatment of each Chinese medicinal herb extract, and the quality control of the composition is facilitated. The Chinese herb extract composition for treating functional gastrointestinal disorder or irritable bowel syndrome, disclosed by the invention, has an unexpected effect.